Mereo BioPharma Group (HAM:MAH0) EV-to-EBIT : -19.82 (As of Jun. 23, 2024)

Mereo BioPharma Group EV-to-EBIT Chart

Mereo BioPharma Group Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBIT		Get a 7-Day Free Trial				-	-	3.43	-1.03	-10.29

Mereo BioPharma Group Quarterly Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial												3.43	-	-1.03	-	-10.29

Competitive Comparison of Mereo BioPharma Group's EV-to-EBIT

For the Biotechnology subindustry, Mereo BioPharma Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mereo BioPharma Group's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's EV-to-EBIT falls into.

Mereo BioPharma Group EV-to-EBIT Calculation

Mereo BioPharma Group's EV-to-EBIT for today is calculated as:

Mereo BioPharma Group's current Enterprise Value is €494.36 Mil.
Mereo BioPharma Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-24.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mereo BioPharma Group  (HAM:MAH0) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Mereo BioPharma Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Mereo BioPharma Group's Enterprise Value for the quarter that ended in Dec. 2023 was €0.00 Mil.
Mereo BioPharma Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-24.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mereo BioPharma Group EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group (HAM:MAH0) Business Description